Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
최신 재무제표(Form-10K)에 따르면, Bio Green Med Solution Inc의 총 자산은 $0이며, 순손실입니다.
BGMS의 주요 재무 비율은 무엇인가요?
Bio Green Med Solution Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Bio Green Med Solution Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Bio Green Med Solution Inc 주요 수익원은 Fire Safety Equipment이며, 최신 수익 발표에서 수익은 603,000입니다. 지역별로는 Malaysia이 Bio Green Med Solution Inc의 주요 시장이며, 수익은 747,000입니다.
Bio Green Med Solution Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Bio Green Med Solution Inc의 순손실은 $0입니다.